Paradise regained: Insights into coronary heart disease prevention from recent clinical trials and basic research

Journal of the Royal College of Physicians of London

Volumn 31, Issue 3, 1997, Pages 263-275

  Lewis, Barry ^a   Watts, Gerald F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; COLESTIPOL; COLESTYRAMINE; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; NUTRITION; PATHOLOGY;

ANTICHOLESTEREMIC AGENTS; CEREBROVASCULAR DISORDERS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; HUMANS; LIPIDS;

EID: 0031007459     PISSN: 00358819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (146)

1. McMichael J. Fats and atheroma - an inquest. Br Med J 1979;1:1182-3.
2. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure and mortality: implications from a cohort of 361,662 men. Lancet 1986;ii:933-6.
3. Rose G, Shipley M. Plasma cholesterol concentration and death from coronary heart disease: 10 year results of the Whitehall study. Br Med J 1986;293:306-7.
4. Armstrong ML, Megan MB. Lipid depletion in atheromatous coronary arteries in Rhesus monkeys after atherogenic and regression diets. Circ Res 1972;30:675-80.
5. Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
6. Frick MH, Elo O, Haapa K, Heinonen OP, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-45.
7. Oliver MF. Reducing cholesterol does not reduce mortality. J Am Coll Cardiol 1988;12:814-7.
8. Jacobs D, Blackburn H, Higgins M, Reed D, et al. Report of the Conference on Low Blood Cholesterol: mortality associations. Circulation 1990;86:1046-60.
9. Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069-118.
10. Morgan RE, Palinkas LA, Barrett-Connor EL, Wingard DL. Plasma cholesterol and depressive symptoms in older men. Lancet 1993;341:75-9.
11. Stamler J. Review of primary prevention trials of coronary heart disease. Acta Med Scand 1985 (Suppl);701:100-28.
12. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990;323:1112-9.
13. Rossouw JE, Lewis B, Rifkind BM. Death from injury, violence and suicide in secondary prevention trials of cholesterol for lowering (letter). N Engl J Med 1992;25:1813.
14. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol lower risk of ischaemic heart disease? Br Med J 1994;308:367-73.
15. Holme I. An analysis of randomised controlled trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990;82:1916-24.
16. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-4.
17. Shepherd J, Cobbe SM, Ford I, Isles CG, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
18. Lewis B. Angiographic trials on progression/regression of atherosclerosis by plasma lipid reduction. In: Gotto AM Jr, Paoletti R, Smith LC, Catapano AL, Jackson AS (eds). Drugs affecting lipid metabolism. Dordrecht: Kluwer Academic Publishers, 1996.
19. Watts GF, Lewis B, Brunt JNH, Lewis ES, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-9.
20. Schuler G, Hambrecht R, Schlierf G, Niebauer J, et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation 1992;86:1-11.
21. Ornish D, Brown SE, Scherwitz LW, Billings JH, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990;336:129-33.
22. Kane JP, Malloy MJ, Ports TA, Phillips NR, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimes. JAMA 1990;264:3007-12.
23. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-40.
24. Buchwald H, Varco RL, Matts JP, Long JM, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990;323:946-55.
25. Haskell WL, Alderman EL, Fair JM, Maron DJ, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project. Circulation 1994;89:975-90.
26. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH, for the Harvard Atherosclerosis Reversibility Project (HARP). Effect on coronary atherosclerosis of decrease in plasmacholesterol concentrations in normocholesterolaemic patients. Lancet 1994;344:1182-6.
27. Thompson GR, Maher VMG, Matthews S, Kitano Y, et al. Familial hypercholesterolaemia regression study: a randomised trial of low-density lipoprotein apheresis. Lancet 1995;345:811-6.
28. Salonen R, Nyyssonen A, Porkkala E, Rummukainen J, et al. Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary prevention trial of the effect of LDL lowering on atherosclerosis progression in carotid and femoral arteries. Circulation 1995;92:1758-64.
29. Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery: two-and four-year old reduction of intima-media thickness measured by ultrasound. Circulation 1993;88:20-8.
30. Furberg CD, Adams HP, Applegate WB, Byington RP, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994;90:1679-87.
31. Crouse JR III, Byington RP, Bond MG, Espelaud MA, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC II). Am J Cardiol 1995;75:455-9.
32. Brown BG, Bolson EL, Dodge ET. Arteriographic assessment of coronary atherosclerosis: review of current methods, their limitations, and clinical applications. Arteriosclerosis 1982;2:2-15.
33. Waters D, Higginson L, Gladstone P, Kimball B, et al. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. CCAIT substudy. Circulation 1995;92:2204-10.
34. Waters D, Higginson L, Gladstone P, Kimball B, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-68.
35. Herd JA, Ballantyne CM, Farmer JA, Ferguson III JJ, et al. The effect of fluvastatin on coronary atherosclerosis: the Lipoprotein and Coronary Atherosclerosis Study (LCAS). Circulation 1996 (Suppl); 941:597 (abstract).
36. Stewart BF, Brown BG, Zhao X-Q, Hillger LA, et al. Benefits of lipid-lowering in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J Amer Coll Cardiol 1994;23:899-906.
37. Watts GF, Jackson P, Mandalia S, Brunt JNH, et al. Nutrient intake and progression of coronary artery disease. Am J Cardiol 1994;73:328-32.
38. Watts GF, Lewis B, Jackson P, Lewis ES, Burke V. Nutritional determinants of atherosclerosis progression in man: the STARS trial. In: Woodford EP, Davignon J, Sniderman A (eds). Atherosclerosis X. Amsterdam: Elsevier Science, 1995;292-7.
39. Blankenhorn DH, Johnson RL, Mack WJ, El Zein, et al. The influence of diet on the appearance of new lesions in human coronary arteries. JAMA 1990;263:1646-52.
40. Watts GF, Jackson P, Burke V, Lewis B. Dietary fatty acids and progression of coronary artery disease in men. Am J Clin Nutr 1996 (in press).
41. Watts GF, Mandalia S, Brunt JNH, Slavin BM, et al. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St Thomas' Atherosclerosis Regression Study (STARS). Metabolism 1993;42:1461-7.
42. Watts GF, Mandalia S, Slavin B, Brunt JMH, et al. Metabolic determinants of the progression of coronary artery disease in men. Clin Chem 1994;40:2240-6.
43. Maher VMG, Brown BG, Marcovina SM, Hillger LA, et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein (a). JAMA 1995;274:1771-4.
44. Thompson GR, Hollyer J, Waters DD. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol 1995;6:386-8.
45. Sacks FM, Gibson M, Rosner B, Pasternak RC, et al. The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Am J Cardiol 1995;76:78c-85c.
46. Sacks FM, Pfeffer MA, Moye LA, Rouleau MD, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
47. The post coronary artery bypass graft trial investigators. The effect of aggressive lowering of LDL cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous vein coronary artery bypass grafts. N Engl J Med 1997;336:153-62.
48. Talmud PJ, Watts GF, McBride S, Mandalia S, et al. Angiotensin converting enzyme gene polymorphism and the course of angiographically defined coronary artery disease. Atherosclerosis 1995;114:133-5.
49. Ye S, Watts GF, Mandalia S, Humphreys SE, Henney AM. Preliminary report: genetic variation in the human stromelysin gene promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995;73:209-15.
50. Cashin-Hemphill L, Mack W, LaBree L, Hodis HN, et al. Coronary progression predicts future cardiac events. Circulation 1993;88:(suppl 1);363.
51. Buchwald H, Matts JP, Fitch LL, Campos CT, et al. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA 1992;268:1429-33.
52. Wissler RW, Vesselinovitch D. Studies of regression of atherosclerosis in experimental animals and man. Ann NY Acad Sci 1976;275:363-78.
53. Heistad DD, Armstrong ML, Marcus ML, Piegors DJ, Mark AL. Augmented responses to vasoconstrictor stimuli in hypercholesterolemic and atherosclerotic monkeys. Circ Res 1984;54:711-8.
54. Vita JA, Treasure CB, Nabel EG, McLenachan JM, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990;81:491-7.
55. Harrison DG, Armstrong ML, Freiman PC, Heistad DD. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987;80:1808-11.
56. Benzuly KH, Padgett RC, Kaul S, Piegors DJ, et al. Functional improvement precedes structural regression of atherosclerosis. Circulation 1994;89:1810-8.
57. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371-7.
58. Lacoste L, Lam JYT, Hung J, Letchacovski G, et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-7.
59. Briner R, Luscher TF. Role of vascular endothelial abnormalities in clinical medicine: atherosclerosis, hypertension, diabetes and endotoxaemia. Adv Intern Med 1994;39:1-22.
60. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991;83:391-401.
61. Egashira K, Inou T, Hirooka Y, Yamade E, et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 1993;91:29-37.
62. Quyyumi AA, Dakak N, Andrews NP, Husain S, et al. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest 1995;95:1747-55.
63. Sax FL, Cannon RO, Hanson C, Epstein SE. Impaired forearm vasodilator response in patients with microvascular angina. N Engl J Med 1987;317:1366-70.
64. Anderson TJ, Uehata A, Gerherd MD, Meredith IT, et al. Close relation of endothelial function in the human coronary and peripheral circulation. J Am Coll Cardiol 1995;26:1235-41.
65. Flavahan NA. Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation 1992;85:1927-38.
66. Leung WH, Lau CP, Wong CK. Beneficial effects of cholesterollowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993;341:1496-1500.
67. Egashira K, Hirooka Y, Kai H, Sugimachi M, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519-24.
68. Treasure CB, Klein JL, Weintraub WS, Stillabower ME, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
69. de Divitiis M, Rubba P, Di Somma S, Ligouri V, et al. Effects of short-term reduction in serum cholesterol with simvastatin in patients with stable angina pectoris and mild to moderate hypercholesterolemia. Am J Cardiol 1996;78:763-8.
70. Anderson TJ, Meredith IT, Yeung AC, Frei B, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl Med 1995;332:388-93.
71. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-21.
72. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72:1031-7.
73. Constantinides P. Plaque fissuring in human coronary thrombosis. Atheroscler Res 1966;6:1-17.
74. Davies M, Thomas AC. Plaque fissuring - the cause of acute myocardial infarction, sudden death and crescendo angina. Br Heart J 1985;53:363-73.
75. Ambrose JA, Winters SL, Stern A, Eng A, et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 1985;5:609-16.
76. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989;ii:941-4.
77. Loree HM, Kamm RD, Stringfellow RG, Lee RT. Effect of fibrous cap thickness on peak circumferential stress in model atherosclerotic arteries. Circ Res 1992;71:850-8.
78. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993;69:377-81.
79. Hackett D, Verwilghen J, Davies G, Maseri A. Coronary stenoses before and after acute myocardial infarction. Am J Cardiol 1989;63:1517-8.
80. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988;12:56-62.
81. Lendon C, Davies M, Born G, Richardson P. Atherosclerotic plaque caps are locally weakened when macrophage density is increased. Atherosclerosis 1991;65:302-10.
82. Hansson GK. Immune and inflammatory mechanisms in the development of atherosclerosis. Br Heart J 1993;69(Suppl): S38.
83. Galis Z, Sukhova G, Lark M, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-505.
84. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991;11:1223-30.
85. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50.
86. Ku G, Doherty NS, Wolos JA, Jackson RL. Inhibition by probucol of interleukin-1 secretion and its implications in atherosclerosis. Am J Cardiol 1988;62:77B-81B.
87. Lipton BA, Partharsarathy S, Ord VA, Clinton SK, et al. Components of the protein fraction of oxidised low density lipoprotein stimulate interleukin-la production by rabbit arterial macrophage-derived foam cells. J Lipid Res 1995;36:2232-42.
88. Chobanian AV, Hollander W. Body cholesterol metabolism in man. 1. The equilibration of serum and tissue cholesterol. J Clin Invest 1962;41:1732-7.
89. Shaikh M, Wootton R, Nordestgaard BG, Baskerville P, et al. Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb 1991;11:569-77.
90. Nordestgaard BG, Tybjaerg-Hansen A, Lewis B. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Arterioscler Thromb 1992;12:6-18.
91. Seddon AM, Woolf N, LaVille A, Pittilo RM, Lewis B. Hereditary hyperlipidemia and atherosclerosis in the rabbit due to overproduction of lipoproteins. Preliminary report of arterial pathology. Arteriosclerosis 1987;7:113-24.
92. LaVille AE, Seddon AM, Rowles PM, Woolf N, Lewis B. Primary prevention of atherosclerosis by lovastatin in a genetically hyperlipidaemic rabbit strain. Atherosclerosis 1989;78:205-10.
93. Small DM, Bond MG, Waugh D, Prack M, Sawyer JK. Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest 1984;73:1590-605.
94. Armstrong ML. Connective tissue in regression. In: Paoletti R, Gotto AM (eds). Atherosclerosis Review vol 3. New York: Raven Press, 1978;147-66.
95. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986;314:488-500.
96. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, et al. Beyond cholesterol: modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
97. Woolf N, Chait A. Atherosclerosis: pathogenesis and factors affecting its progression. In: Cohen RD, Lewis B, Alberti KGMM, Denman AM (eds). The metabolic and molecular basis of acquired disease, vol 2. London: Baillière Tindall, 1990;1530-69.
98. Lewis B, Paoletti R, Tikkanen MJ (eds). Low blood cholesterol: health implications. London: Current Medical Literature, 1993.
99. Lewis B, Tikkanen MJ. Low blood total cholesterol and mortality. Causality, consequence and confounders. Am J Cardiol 1994;73:80-5.
100. Winawer SJ, Flehinger BJ, Buchalter J, Herbert E, Shike M. Declining serum cholesterol prior to diagnosis of colon cancer. A time trend case-control study. JAMA 1990;263:2083-5.
101. International Collaborative Group. Circulating cholesterol level and risk of death from cancer in men aged 40 to 69 years. JAMA 1982;248:2853-9.
102. Law MP, Thompson SG. Serum cholesterol and cancer. Conclusions from an analysis of data from all the prospective studies. Cancer Causes Control 1991;2:253-61.
103. Klag MJ, Ford DE, Mead LA, He J, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 1993;328:313-8.
104. Smith CD, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol concentration and mortality. The Whitehall study. JAMA 1992;267:70-6.
105. Irribaren C, Reed DM, Wergoske G, Burdifiel CM, et al. Serum cholesterol level and mortality due to suicide and trauma in the Honolulu Heart Program. Arch Intern Med 1995; 155:695-700.
106. Wysowski DK, Gross TP. Deaths due to accidents and violence in two recent trials of cholesterol-lowering drugs. Arch Intern Med 1990;150:2169-72.
107. Iso H, Jacobs DR Jr, Wentworth D, Jacobs JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 1989;320:904-10.
108. Oliver MF. Might treatment of hypercholesterolaemia increase non-cardiac mortality? Lancet 1991;339:1529-31.
109. Cutts AL, Bankhurst AD. Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutarylcoenzyme A reductase by lovastatin. Int J Immunopharmacol 1989;8:863-9.
110. Marenah CB, Lewis B, Hassall D, La Ville A, et al. Hypocholesterolaemia and non-cardiovascular disease: metabolic studies on subjects with low plasma cholesterol concentrations. Br Med J 1983;286:1603-6.
111. McPherson R, Tsoukas CM, Baines MG, Vost A, Pross HE. Effects of lovastatin on natural killer cell function and other immunological parameters in man. XI International symposium on drugs affecting lipid metabolism, Florence, 1992. LorenziniFoundation Symposium 1992;222:7(abstract).
112. Goldstein JL, Brown MS. Lipoprotein receptors: genetic defense against atherosclerosis. Clin Res 1982;30:417-26.
113. Dietschy JM. Regulation of cholesterol metabolism in man and in other species. Klin Wochenschr 1984;62:338-45.
114. Belknap WM, Dietschy JM. Sterol synthesis and low density lipoprotein clearance in vivo in the pregnant rat, placenta, and fetus. J Clin Invest 1988;82:2077-85.
115. Dietschy JM. Alterations in plasma LDL cholesterol levels do not alter cholesterol homeostasis across the extrahepatic organs. In: Lewis B, Paoletti R, Tikkanen MJ (eds). Low blood cholesterol: health implications. London: Current Medical Literature, 1993:43-53.
116. Law MB, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA Study. Br Med J 1994;308:363-6.
117. Working Party of the International Task Force for the Prevention of Coronary Heart Disease/European Atherosclerosis Society. Prevention of coronary heart disease. Scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992;2:113-56.
118. Smith DG, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. Br Med J 1993;306:1367-73.
119. Brown G, Albers JJ, Fisher LD, Schaefer SM, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
120. Mintz GS, Painter JA, Prichard AD, Kent KM, et al. Atherosclerosis in angiographically 'normal' coronary artery reference segments: an intravascular ultrasound study with clinical correlations. J Am Coll Cardial 1995;25:1479-85.
121. Detrano RC, Wong ND, Tang W, French WJ, et al. Prognostic significance of cardiac cinefluoroscopy for coronary calcific deposits in asymptomatic high risk subjects. J Am Coll Cardiol 1994;24:354-8.
122. Janowitz WR, Agatston AS, Kaplan G, Viamonte M Jr. Differences in prevalence and extent of coronary artery calcium detected by ultrafast computed tomography in asymptomatic men and women. Am J Cardiol 1993;72:247-54.
123. Lees RS. Non-invasive detection of vascular function and dysfunction. Curr Opin Lipidol 1993;4:325-9.
124. Gould KL. Reversal of coronary atherosclerosis. Clinical promise as the basis for non-invasive management of coronary artery disease. Circulation 1994;90:1558-71.
125. Galgee MA, van Rossum AC, Doesburg T, van Eenige MJ, et al. Value of magnetic resonance imaging in assessing patency and function of coronary artery bypass grafts. Circulation 1996;93:660-6.
126. Toussaint J-F, LaMuraglia GM, Southern JF, Fuster G, et al. Magnetic resonance images: lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation 1996;94:932-8.
127. De Feyter PJ. Current status of techniques for diagnosing atherosclerosis. Curr Opin Lipidol 1990;1:346-51.
128. McGill HC Jr. Introduction to the geographic pathology of atherosclerosis. Lab Invest 1968;18:465-653.
129. Craven TE, Ryu JE, Espeland MA, Kahl FR, et al. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis: case-control study. Circulation 1990;82:1230-42.
130. Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb 1991;11:1245-9
131. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
132. Lewis B. Hyperlipidaemia. In: Cohen RD, Lewis B, Alberti KGMM, Denman AM (eds). The metabolic and molecular basis of acquired disease, vol 1. London: Baillière Tindall, 1990;860-920.
133. Glatz JFC, Turner PR, Katan MB, Stalenhoef AFH, Lewis B. Hypo-and hyperresponse of serum cholesterol level and low density lipoprotein production and degradation to dietary cholesterol in man. Ann NY Acad Sci 1993;676:163-79.
134. Ramsay LE, Yeo WW, Jackson PR. Dietary reduction of serum cholesterol concentration: time to think again. Br Med J 1991;303:953-7.
135. Hunninghake DB, Stein FA, Dujovne CA, Harris WS, et al. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med 1993;328:1213-9.
136. Lewis B, Hammett F, Katan MB, Kay RM, et al. Towards an improved lipid-lowering diet: additive effects of changes in nutrient intake. Lancet 1981;ii:1310-3.
137. Rifkind BM, Goor R, Schucker B. Compliance and cholesterol lowering in clinical trials: efficacy of diet. In: Schettler FG, Gotto AM, Middelhoff G, Schlierf G, et al (eds). Atherosclerosis VI. Berlin: Springer-Verlag, 1983;306-10.
138. The Surgeon General's report on nutrition and health. Washington, US Department of Health and Human Services, 1988.
139. Hjermann I, Velve Byre K, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Lancet 1981;ii:1303-10.
140. Choudhury S, Hammett F, Katan MB, Marenah CB, et al. A multifactorial diet in the management of hyperlipidaemia. Atherosclerosis 1994;50:90-103.
141. Schaefer EJ, Lichtenstein AH, Lamon-Fava S, Contois JH, et al. Efficacy of a national cholesterol education program step 2 diet in normolipidemic and hypercholesterolemic middle-aged and elderly men and women. Arterioscler Thromb Vasc Biol 1995;15:1079-85.
142. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res 1990;31:1149-72.
143. Stamler J. Nutrition-related risk factors for the atherosclerotic diseases - present status. Prog Biochem Pharm 1983;19:245-308.
144. Shekelle RB, Shryock AM, Paul O, Lepper M, et al. Diet, serum, cholesterol, and death from coronary heart disease. N Engl J Med 1981;304:65-70.
145. Oliver MF. Why measure cholesterol after myocardial infarction, and when? (editorial) Br Med J 1984;289:1641-2.
146. Lewis B. On lowering lipids in the post-infarction patient. J Intern Med 1991;229:483-8.